ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

admin

3 years ago

Philadelphia, PA (November 11, 2020) "“ Oncoceutics, Inc. announced that the latest research on imipridones ONC201 and ONC206 for the treatment of brain tumors will be presented at the 2020 Society of Neuro-Oncology Virtual Annual Meeting to be held November 19th-21st.

These data will highlight clinical and translational findings over the past year, including:

Updated interim efficacy results for the ONC201 registration cohort in recurrent H3 K27M-mutant gliomas
Clinical safety, pharmacokinetics, and clinical outcomes for ONC201 in H3 K27M-mutant gliomas
Mechanism of action studies of ONC201 revealing new aspects of how it uniquely acts against brain tumors
Biodistribution and metabolism studies of ONC201, highlighting that ONC201 is distributed throughout targeted brain substructures
IND-enabling studies, predictive biomarkers and first-in-human trial design for ONC206
Distinctions between the potency, target engagement, and resistance mechanisms for ONC201 and ONC206
Preclinical efficacy and mechanism of action of ONC206 alone and in combination with other treatments, including ONC201, in specific brain tumors

Summaries and presentation information are provided below:

Format	Abstract/Title	Presenter
ONC201: Clinical
Oral	Efficacy of ONC201 in patients with recurrent H3 K27M-mutant diffuse midline glioma	Dr. Isabel Arrillaga-Romany, MD, PhD, Massachusetts General Hospital
Oral	Clinical efficacy of ONC201 in newly diagnosed DIPG and in previously irradiated pediatric H3 K27M-mutant gliomas	Sharon L. Gardner, MD, New York University
Oral	Clinical efficacy of ONC201 in H3 K27M-mutant diffuse midline glioma requires EGFR/FOXG1 independence	Abed Kawakibi, University of Michigan
ONC201: Preclinical
Oral	Cellular stress response in DIPG therapy	Vidya Gopalakrishnan, PhD, M.D. Anderson Cancer Center
Poster	CYP450 and metabolic profiling of anti-cancer imipridone ONC201	Sara Morrow, Oncoceutics
Poster	ONC201 exhibits passive diffusion and broad distribution in the central nervous system	Sara Morrow, Oncoceutics
ONC206
Oral	IND-enabling characterization of dual DRD2- and ClpP-targeting agent ONC206 as the next imipridone for clinical neuro-oncology	Varun V. Prabhu, PhD, Oncoceutics
Poster	Preclinical efficacy of the imipridone ONC206 against medulloblastoma	Tobey J. MacDonald, MD, Emory University
Poster	Molecular differentiation of imipridones ONC201 and ONC206	Varun V. Prabhu, PhD Oncoceutics
Poster	Biomarker evaluation for imipridone ONC206 reveals ClpP, ATF4, MYC, EGFR and HIF1 as key predictors of anti-cancer efficacy	Sara Morrow, Oncoceutics
Combinatorial Efficacy: Preclinical
Poster	Synergistic tumor suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitor provides a novel treatment strategy for GBM and DMG	Wafik El-Deiry, MD, PhD, Brown University
Poster	International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for diffuse midline gliomas	Javad Nazarian, PhD, University Children"™s Hospital Zurich

About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. ONC201 is an orally active small molecule DRD2 antagonist and ClpP agonist in late-stage clinical development for H3 K27M-mutant glioma with additional indications under clinical investigation. ONC206 is the second clinical-stage imipridone that is under clinical investigation for central nervous system tumors. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships. Visit Oncoceutics.com for more information.